Summit Therapeutics Share Price (SUMM)

187.50 -2.50 (-1.32%) delayed: 1:25PM BST
Bid price 180.00 Open price 190.00
Ask price 195.00 Prev close 190.00
High price 190.00 Spread 7.69%
Low price 181.00 Volume 8,967

Register now for FREE live Summit Therapeutics share prices, Summit Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Summit Therapeutics Level 2 Data, indepth research tools and investor commentary for Summit Therapeutics (SUMM) and other London Stock Exchange equities.

Summit Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Summit Therapeutics share price charts

Summit Therapeutics Share Price Information

Name Summit Therapeutics Epic SUMM
Sector Pharmaceuticals & Biotechnology ISIN GB00BN40HZ01
Activites Summit Therapeutics plc (formerly Summit Corporation plc, formerly VASTox plc) is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit's goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Index n/a

Summit Therapeutics Key Numbers

Latest Share Price (p) 187.50 Net Gearing (%) 34.64
Market Capitalisation (£m) 117.66 Gross Gearing (%) 109.29
Shares in issue (m) 61.93 Debt Ratio 113.09
P/E Ratio -4.32 Debt-to-Equity Ratio 0.74
Total dividends per share (p) 0.00 Assets / Equity Ratio -10.76
Dividend Yield (%) 0.00 Price to book value -26.74
Dividend cover (x) 0.00 ROCE (%) -96.31
Earning per share (p) -44.00 EPS Growth (%) -7.32
52 week high / low 265.00 / 86.50 DPS Growth (%) n/a

Summit Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
30/07/2014 BUY Glyn Edwards CEO 30,000
26/07/2013 PLAC Glyn Edwards CEO 600,000
26/07/2013 PLAC Dr Frank Armstrong CH 50,000
26/07/2013 PLAC Barry Price NED 500,000
26/07/2013 PLAC Jim Mellon RES 20,000,000

More Summit Therapeutics Director Deals >>

Summit Therapeutics Company News

18:00 18/09/2017

Summit Therapeutics Announces Closing of its ADS Public Offering Raising USD20.1M Before Expenses

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS ANNOUNCES CLOSING OF ITS PUBLIC...

18:29 15/09/2017

Summit Therapeutics Announces Exercise of Underwriters' Over-Allotment Option

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS ANNOUNCES EXERCISE OF...

07:00 14/09/2017

Summit Announces Underwritten Public Offering of 1,459,000 ADSs to Raise USD17.5 Million Before Expenses

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS ANNOUNCES UNDERWRITTEN PUBLIC...

More Summit Therapeutics Company News >>

Register now for FREE Summit Therapeutics company news

Summit Therapeutics Share Price Discussions

8 days ago

Summit Corporation PLC (SUMM)

http://www.summitplc.com/ Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease...

more than 1 year ago

Summer Bonanza is upon us.......... (SUMM)

OK folks it's mid March and spring is upon us. Time to start looking ahead, the mkts have had a bit of a setback, is this the healthy correction that's been spoken about for so long or is it a buying opportunity on the road to new highs? Who knows, not me for sure, if I did I'd tell ya'll after...

Register now for FREE Summit Therapeutics share price discussions